fatigue) and symptomatic supraventricular arrhythmias (atrial fibrillation, atrial flutter, atrial tachycardia or sick sinus syndrome). Other complications include paradoxical emboli, heart failure or right ventricular (RV) failure, and pulmonary vascular disease (the latter occurs in 5% to 9% of patients).
Any condition causing reduced left ventricular (LV) compliance (eg, aging, LV hypertrophy due to hypertension, cardiomyopathy or myocardial infarction) will tend to increase the left-to-right shunt through an ASD, and worsen symptoms. This may justify closure of defects considered to be anatomically borderline.
Part IV. Diagnostic workup The initial workup should include the following (at a minimum):
A thorough clinical assessment.
• Electrocardiogram (ECG).
• Chest x-ray. • Transthoracic echocardiographic (TTE)-Doppler evaluation by an • appropriately trained individual. In some cases, contrast echocardiography (echo) with a saline contrast injection may be needed to determine whether there is an intracardiac shunt. Transesophageal echo (TEE)-Doppler examination to prove the • existence of one or more ASDs, better define its/their location(s), size(s) and shape(s), assess pulmonary venous connections and evaluate the cardiac valves, if this information is not provided by TTE. TEE is mandatory to determine whether the ASD is suitable for device closure.
Resting oxygen saturation. •

An adequate diagnostic workup includes cardiac imaging to assess the following:
The presence and type of ASD(s).
• The size (diameter) of the defect(s). •
The functional importance of the defect as manifested by: • shunt size (pulmonary-to-systemic flow ratio [Qp:Qs]); RV size, function and volume overload, and right atrial size; and pulmonary artery pressures (PAPs) and, if elevated, pulmonary vascular resistance. Other associated conditions that may influence management • (eg, anomalous pulmonary venous connection, significant valve disease or coronary artery disease).
The diagnostic workup may require the following:
Heart catheterization (if determination of PAPs and resistances is • needed to assess pulmonary vascular reactivity or to delineate anomalous pulmonary venous connections). Coronary angiography in patients at high risk of coronary artery • disease or in patients older than 40 years of age if surgical or device repair is planned. Magnetic resonance imaging (MRI) to prove the existence of an • ASD (although TEE is the superior imaging method), to estimate Qp:Qs, to determine the size and function of the right ventricle, and to assess pulmonary venous connections if doubts remain after other imaging modalities. Contrast-enhanced cine computed tomography (CT) can also be • used to determine RV size and function, and pulmonary vein anatomy; however, because of the associated radiation exposure, CT imaging should only be used when other imaging modalities are unable to provide sufficient information. Oxygen saturation with exercise if there is any suggestion of • pulmonary hypertension. If there is severe pulmonary hypertension or a resting oxygen saturation of less than 85%, exercise should be avoided. Genetic assay for a • TBX5 mutation can confirm the diagnosis of the Holt-Oram syndrome in suspected cases. However, the absence of a TBX5 mutation does not preclude the diagnosis.
Genetic testing is helpful in establishing the diagnosis in family members of a patient with a known TBX5 mutation (3, 4) .
Part V. Indications for intervention/reintervention/medical therapy
Surgical or percutaneous closure of an ASD is indicated in the presence of a hemodynamically significant ASD with or without resulting symptoms. A hemodynamically significant ASD is defined as an ASD with resultant RV volume overload as measured by echo or MRI.
Class I, level B (5-15)
Closure of an ASD may be indicated in patients with orthodeoxia-platypnea. Closure of an ASD may be indicated in patients with paradoxical emboli. Surgical closure of an ASD should be considered if patients are undergoing tricuspid valve repair or replacement. Class IIa, level C (10,16)
In a patient with an unrepaired ASD, venous thromboemboli from any source are a particular hazard because of the risk of paradoxical emboli.
Closure can be considered if pulmonary arterial hypertension (PAH) is present and there is a net left-to-right shunt of greater than 1.5:1; or evidence of pulmonary artery reactivity when challenged with a pulmonary vasodilator (eg, oxygen, nitric oxide and/or prostaglandins). Such patients should receive care from a specialist with expertise in PAH.
Class IIa, level C (17-19)
If PAH is present (PAP of greater than two-thirds the systemic arterial blood pressure [SABP] or pulmonary arteriolar resistance of greater than two-thirds the systemic arteriolar resistance) and there is irreversible PAH, the ASD should not be closed. Such patients should receive care from a specialist with expertise in PAH.
Class III, level C (20,21)
Arrhythmia interventions (catheter ablation or surgical maze procedure) should be considered in patients with atrial tachyarrhythmias. Catheter ablation should be considered before device closure, while surgical maze would be performed concomitant with ASD closure. Transvenous pacing should be avoided in patients with unrepaired ASDs because paradoxical emboli may occur.
Class IIa, level B (22,23)
If closure of ASDs is being planned, it is recommended that closure be performed without undue delay before 24 years of age to ensure mortality benefit from surgery, and probably before 40 years of age for arrhythmia benefit for either surgery or device closure). As a rule, younger patients have a better prognosis after repair (6, 22, (24) (25) (26) .
Part VI. Surgical/interventional technical options
In patients with secundum ASD, percutaneous ASD closure is the most frequently used closure method, and offers results comparable with surgical closure (9, (27) (28) (29) . The procedure is guided by either TEE or intracardiac echo. After percutaneous ASD closure, a TTE should be performed at 24 h after implantation to ensure that there is no significant pericardial effusion. Antiplatelet therapy with acetylsalicylic acid is usually given for six months following device closure.
Patients who undergo device closure must be 'ready' to undergo a surgical procedure in the event of complications.
Percutaneous ASD closure should be performed by individuals with expertise in the technique and its clinical evaluation. Class I, level C Surgical closure may also be offered, and may be especially attractive should the patient prefer the time-honoured surgical approach, or especially if atrial arrhythmia surgery (atrial maze procedure for atrial fibrillation, and radiofrequency or cryoablation for atrial flutter) is offered concurrently. Catheter-based ablation techniques may be an alternative and should be attempted before device closure. Surgical approaches, such as the inframammary, right mini thoracotomy or mini sternotomy approach to a typical secundum ASD should be made known to interested patients considering surgery.
In patients with large secundum ASDs (larger than 38 mm) not amenable to device closure, surgical closure should be undertaken. Patients with a sinus venosus defect or ostium primum ASD cannot be closed by percutaneous devices and should be surgically repaired by congenital heart surgeons. Potential complications after percutaneous ASD closure are rare and include residual shunting, PAH, new-onset or recurrent arrhythmias, device embolization, device erosion, device impingment on valves, veins or other vessels such as the aorta, cardiac tamponade, thrombosis arising on the device, clinical right heart failure (typically in patients with elevated PAPs) and endocarditis. Small residual shunts in patients with normalized RV volumes require no specific additional treatment.
After percutaneous device insertion, chest pain or syncope may represent device erosion and should be evaluated immediately, preferably at a centre that performs cardiac surgery. After percutaneous device insertion, early (three months) and intermediate (one year) follow-up is recommended with echo surveillance. Periodic follow-up is required thereafter.
Class I, level C
Surgical closure: For secundum ASD without pulmonary hypertension, surgical closure should result in a very low (less than 1%) operative mortality. Early and long-term follow-up is excellent.
Potential postoperative complications include death, residual shunting, PAH, arrhythmias, postpericardiotomy syndrome, cardiac tamponade and right heart failure. LV failure may occur in patients with associated cardiovascular disease (eg, coronary artery disease, hypertension, mitral valve incompetence).
Postoperative ASD patients may be prone to cardiac tamponade for the first several weeks after surgery. The presence of preoperative atrial flutter/fibrillation may warrant surgical closure of the defect with concomitant cryosurgical/ablative therapy or an atrial maze procedure. Whereas atrial macro-reentrant tachyarrhythmias may usually be addressed by a right-sided atrial maze, atrial fibrillation requires a left-sided maze as well (33, 34) .
In patients with sustained atrial arrhythmias under consideration for transcatheter ASD closure, referral to an electrophysiologist is recommended. Catheter ablation should be considered before ASD closure because the presence of a septal closure device will impede access to the left atrium. Class IIb, level C Part IX. Pregnancy and contraception Pregnancy is well tolerated in patients after ASD closure. In general, pregnancy is well tolerated in women with unrepaired ASDs, but the risk of paradoxical embolism is increased during pregnancy and the postpartum period. Global (ventricular systolic dysfunction, degree of cyanosis, history of cardiac complications) (35) and lesion-specific risks need to be taken into account when determining the risk of pregnancy.
Pregnancy in women with Eisenmenger's syndrome is not advised because of the high maternal and fetal mortality.
Class III, level B (36-39)
The rate of transmission of congenital heart disease (CHD) to offspring of women with sporadic secundum ASD is approximately 5% to 10%.
Part X. Follow-up
It is advisable that adults with repaired ASDs who have the following features undergo periodic follow-up by an adult CHD (ACHD) cardiologist:
• Repair completed as an adult.
• Elevated PAP at the time of repair.
• Atrial arrhythmias pre-or postoperatively.
• Ventricular dysfunction preoperatively.
• Coexisting heart disease (eg, coronary artery disease, valvular heart disease, hypertension).
• Familial ASD with Nkx2.5 gene mutations because of the risk of progressive AV block.
Class I, level C
Endocarditis prophylaxis is recommended for six months following ASD closure (surgical or device). Acetylsalicylic acid is recommended for six months following percutaneous device closure of an ASD.
Class I, level C (40)
For patients with unrepaired ASD, clinical examinations and TTEs should be performed periodically. TTE should re-examine RV size and function, and assess pulmonary artery systolic pressure.
Endocarditis prophylaxis is not recommended in patients with an isolated ASD or a repaired (surgical/device) ASD without residual shunt.
Class III, level B (40)
VENTRICULAR SEPTAL DEFECT Part I. Background information Only isolated ventricular septal defects (VSD) will be considered. Eisenmenger's VSD is further discussed in a separate section of the present guidelines series.
Hemodynamic severity grading of isolated VSD in adults (40):
Small: Pressure low (pulmonary/aortic systolic pressure ratio of less than 0.3 or main pulmonary artery mean pressure of lower than 20 mmHg or main pulmonary systolic artery pressure of lower than 35 mmHg) and Qp:Qs of less than 1.5:1. VSDs may coexist with other cardiac lesions such as valvar or subvalvar pulmonary stenosis, transposition of the great arteries, subaortic stenosis and coarctation of the aorta, and may result in aortic regurgitation from aortic cusp prolapse.
Part II. Prevalence and genetics
Subarterial VSDs are more common in Asian patients. Inlet VSDs typically occur in patients with Down's syndrome. VSDs can occur in the context of several deletion syndromes, chromosomal disorders, single gene defects and following exposure to certain teratogens such as alcohol. VSDs that occur in the context of other associated anomalies or in the context of a positive family history of birth defects, require further genetic evaluation.
Part III. History and management of unoperated patients
Small VSDs are associated with a normal life expectancy. They present as systolic murmurs. Atrial arrhythmias may occur. Spontaneous closure of small VSDs can still occur occasionally in adult life (41) (42) (43) .
Moderate VSDs are unusual in the adult, but may occur when a prolapsing aortic valve cusp partially obstructs the defect. They are associated with the development of left heart dilation and shuntrelated pulmonary hypertension (which often reverses with correction of the defect), and resultant congestive heart failure and atrial fibrillation.
Large VSDs without pulmonary hypertension exist in adults only when associated with obstruction to RV outflow, and are rare. These patients are at risk for endocarditis, especially if they are cyanotic because of severe RV outflow tract obstruction at the infundibular or valvular level, with secondary right-to-left shunt through the VSD.
VSD patients with Eisenmenger's syndrome (see section on Eisenmenger's syndrome) are at continuous risk for mortality and morbidity. Poor prognostic features are atrial flutter/fibrillation, syncope, heart failure, hemoptysis and aneurysmal dilation of proximal hypertensive pulmonary arteries, which may rupture, even with laminated thrombus in such dilated arteries.
Five per cent of VSDs develop aortic valve regurgitation (41, 42) . Patients with subarterial VSD are more likely to develop aortic regurgitation from progressive prolapse of the aortic valve cusps than those with a perimembranous VSD (41). • A perimembranous or subarterial VSD with more than mild aortic incompetence. • In the presence of severe pulmonary hypertension (PAP greater than two-thirds the SABP or pulmonary arteriolar resistance greater than two-thirds the systemic arteriolar resistance), there must be a net left-to-right shunt of at least 1.5:1, or evidence of pulmonary artery reactivity when challenged with a pulmonary vasodilator (eg, oxygen, nitric oxide and/or prostaglandins).
Part IV. Diagnostic workup
Class I, level B (42-47)
The following situations may warrant closure:
• A history of endocarditis (especially recurrent).
• If transvenous pacing is required, closure may be reasonable to prevent paradoxical emboli. Class IIa, level B (23,48) If PAH is present (PAP greater than two-thirds the SABP or pulmonary arteriolar resistance greater than two-thirds the systemic arteriolar resistance) and irreversible, the VSD should not be closed. Such patients should receive care from a specialist with expertise in PAH. Success rates of device closure are between 90% and 95% (50-52). Complications of interventional closure have been reported in 10% of patients and include hypotension, device embolization, rhythm and conduction abnormalities, and new aortic or tricuspid regurgitation. The major concern of device closure of perimembranous VSD is the 1% to 6% incidence of complete AV block that can occur early or late after closure (51) .
Elevated PAPs preoperatively may progress, regress or remain unchanged postoperatively.
Part VIII. Arrhythmias
Atrial fibrillation may occur, especially if there has been longstanding volume overload of the left heart, or if other reasons for left atrial dilation are present.
Patients with unoperated VSDs experience an increased prevalence of isolated premature ventricular contractions, couplets, multiform premature ventricular contractions and nonsustained ventricular tachycardia, particularly in association with higher PAPs. Late ventricular arrhythmias and sudden death are potential risks, especially in patients repaired late in life (44, 53, 54) .
Complete heart block may also occur early or late after surgical repair (1% to 4%) (54).
Part IX. Pregnancy and contraception
Pregnancy is well tolerated in women with small or moderate VSD, and in women with repaired VSDs. Global (ventricular systolic dysfunction, degree of cyanosis, history of cardiac complications) (35) and lesion-specific risks need to be taken into account when determining the risk of pregnancy.
Class III, level B (36-39) Part X. Follow-up
Patients with the following problems benefit from periodic evaluation by an ACHD cardiologist (Level C):
• Patch leaks or residual VSDs (which seldom require reoperation).
• Elevated pulmonary vascular resistance at the time of surgery.
• Aortic valve surgery.
• Late repair of moderate or large defects.
• Residual right or LV dysfunction.
• Significant atrial or ventricular arrhythmias.
• Associated cardiac lesions (eg, RV outflow tract obstruction or aortic regurgitation). Endocarditis prophylaxis is recommended for six months following VSD closure (surgical or device) or for life if any residual defect persists after surgical or device closure. The terms AVSDs, AV canal defects and endocardial cushion defects can be used interchangeably to describe this group of defects. AVSDs cover a spectrum of anomalies caused by abnormal development of the endocardial cushions. The defect may be only at the atrial level (ostium primum ASD) or may include an inlet-type VSD. The AV valves are fundamentally abnormal, being derived from five leaflets (a right anterosuperior leaflet, a right inferior leaflet, a superior bridging leaflet, an inferior bridging leaflet and a left mural leaflet). This may result in separate right and left AV valves (with the left AV valve having a 'cleft' at the junction of the superior and inferior bridging leaflets) or a common valve (see classification below). Eisenmenger's AVSD is further discussed in a separate section of the present guidelines series.
Classification:
Partial AVSD: The ventricular septum is intact. There is a primum ASD. There is a 'cleft' in the left AV valve. There are two separate AV valve annuli. Intermediate AVSD: This is the rarest form, and part of a spectrum between complete and partial AVSD. It is characterized by a restrictive VSD, a primum ASD and a cleft mitral valve. The anterior and posterior bridging leaflets are fused, resulting in two distinct AV valve components. Complete AVSD: There is a nonrestrictive inlet-type VSD. There is usually a primum ASD but, rarely, the atrial septum may be intact. There is a common AV orifice.
Part II. Prevalence and genetics
AVSD may coexist with other lesions, both cardiac and noncardiac. The most common association is with Down's syndrome. Down's syndrome is present in 35% to 60% of patients with AVSD. Approximately 70% of patients with Down's syndrome have AVSDs. While AVSD can also occur in the context of chromosomal abnormalities, including trisomies 13 and 18, as well as in deletion and duplication syndromes, it is more frequently encountered in patients with genetic syndromes such as Smith-Lemli-Opitz, Smith-Magenis and Williams syndromes. Patients with Down's syndrome have a tendency for premature pulmonary vascular disease irrespective of the type of AVSD. Most (more than 90%) partial AVSDs occur in non-Down's syndrome patients. AVSD may occur in association with tetralogy of Fallot and other forms of complex CHD.
Part III. History and management of unoperated patients
Clinical presentation will depend on the presence and size of the ASD and VSD, and competence of the left AV ('mitral') valve.
Clinical presentation may take several forms: Symptoms of heart failure or pulmonary vascular disease. Symptoms include decreased exercise tolerance, fatigue, dyspnea, arrhythmias and recurrent pulmonary infections. Symptoms increase with age and most adults are symptomatic by 40 years of age. Patients become symptomatic at a younger age if significant left AV valve regurgitation is present. Complete AVSD: Most patients with complete defects will have been repaired in infancy, although some may have been palliated with pulmonary artery bands and have variable degrees of pulmonary vascular obstructive disease. The history of unoperated complete AVSD is that of Eisenmenger's syndrome, and is discussed in the Eisenmenger's section. AVSD with Eisenmenger's syndrome has a worse prognosis than ASD, VSD or patent ductus arteriosus (PDA) with Eisenmenger's syndrome. Poor prognostic features are atrial flutter/fibrillation, syncope, heart failure and hemoptysis. TEE to determine the exact anatomy (if unclear after TTE); the • presence of intracardiac shunts; chordal attachments; the presence and severity of left AV ('mitral') valve regurgitation (or stenosis if previous valve repair has been undertaken); the presence and severity of right AV valve regurgitation and subaortic stenosis. Heart catheterization to determine the presence and magnitude of • intracardiac shunts; PAPs and resistances; the severity of pulmonary vascular disease (with or without reversibility using oxygen, nitric oxide and/or prostaglandins); the presence and severity of left AV ('mitral') valve regurgitation (or stenosis, if previous valve repair has been undertaken); the presence and severity of subaortic stenosis (provocative testing may be necessary). Coronary angiography in patients at risk for coronary artery disease • or in patients older than 40 years of age if an intervention is planned. Holter monitoring to assess AV block or other arrhythmia. • MRI to help define the anatomy. MRI can also be used to • estimate Qp:Qs.
Part IV. Diagnostic workup
Part V. Indications for intervention/reintervention/medical therapy
The following situations warrant intervention/reintervention:
• An unoperated AVSD with: a. Presumed paradoxic emoblism. b. LV dysfunction. If PAH is present (PAP greater than two-thirds the SABP or pulmonary arteriolar resistance greater than two-thirds the systemic arteriolar resistance) and irreversible, the AVSD should not be closed. Such patients should receive care from a specialist with expertise in CHD and PAH. Class III, level C Transvenous pacing should be avoided if there are residual interatrial or interventricular communications because paradoxical emboli may occur.
Class I, level B (23) Part VI. Surgical technical options
A primum ASD (partial AVSD) cannot be closed using a percutaneous device and should be surgically repaired by a congenital heart surgeon. AVSD patients, including those with ostium primum ASD, left AV ('mitral') valve repair, subaortic stenosis or residual defects, should be operated on by congenital heart surgeons.
Class I , level C (30-31)
When left AV valve repair is not possible, valve replacement may be necessary. The operative risk of valve replacement surgery should be similar to routine mitral valve replacement, although the risk of complete AV block may be higher.
Part VII. Surgical outcomes
In the short term, the results of repair of partial AVSD are similar to those following closure of secundum ASD, but sequelae of left AV ('mitral') valve regurgitation, subaortic stenosis and AV block may develop or progress (58) (59) (60) (61) (62) .
In general, late results after left AV valve repair for these patients have been excellent, with the need for surgical revision in approximately 5% to 10% of patients (59) (60) (61) . Occasionally, repair of the abnormal left AV valve may result in a stenotic valve, which may necessitate reoperation. Subaortic stenosis will develop or progress in up to 5% of patients after repair, particularly in patients with primum ASD and some complete defects, especially if the left AV valve has been replaced. The long-term results of repair of complete AVSD are not well known but similar problems, as with partial AVSD, are likely.
Part VIII. Arrhythmias
Characteristic ECG features in the adult with AVSD include firstdegree AV block, an incomplete or complete right bundle branch block pattern, and moderate to extreme left-axis deviation. Persistent complete AV block may occur spontaneously, immediately postoperatively or late after repair. Atrial fibrillation or flutter are not uncommon in adults with AVSD. Sinus node dysfunction and increased ventricular ectopy may also occur.
Part IX. Pregnancy and contraception
Pregnancy is well tolerated in patients with complete repair and no significant residual lesions. Women in New York Heart Association class I and II with unoperated partial AVSD usually tolerate pregnancy very well, but have an increased risk of paradoxical embolization. Global (ventricular systolic dysfunction, degree of cyanosis, history of cardiac complications) (35) and lesion-specific risks need to be taken into account when determining the risk of pregnancy.
Trisomy 21 patients have a 50% risk of transmitting trisomy 21 or other genetic defects to their offspring.
All women with AVSD should be evaluated before conception to assess for possible hemodynamically significant lesions that might complicate management of pregnancy. Consideration should be given to closure of any significant AVSD before pregnancy to minimize the risk of paradoxical emboli. Reproductive counselling is warranted for trisomy 21 patients. Class I, level C Pregnancy in women with Eisenmenger's syndrome is not recommended because of the high maternal and fetal mortality. 
Part II. Genetics
Familial PDA is seen with Char syndrome, an autosomal dominant disorder caused by mutations of TFAP2B characterized by abnormal facies and aplasia/hypoplasia of the middle phalanges of the fifth fingers (63) .
Part III. History and management of unoperated patients
The risk of endarteritis with small silent PDA is unknown, but is likely very low (only sporadic case reports exist).
All other PDAs are associated with a rare risk of endarteritis, which may increase with age.
Adults with a small PDA have a normal life expectancy. A moderate PDA is unusual in adults. It is associated with the development of left heart dilation and shunt-related pulmonary hypertension (which often reverses with correction of the defect). The majority of patients are symptomatic from dyspnea or palpitations (atrial arrhythmias), although frank heart failure is unusual.
A large PDA is rare in the adult, most having been corrected in infancy and childhood. Pulmonary hypertension is usual and may not reverse entirely with closure of the defect. Most patients are symptomatic from dyspnea or palpitations. Aneurysmal enlargement of the duct is an uncommon but important complication.
Eisenmenger's PDA has a similar prognosis to Eisenmenger's VSD, although symptoms may be less marked and exercise tolerance better. Patients will have differential cyanosis and, therefore, oxygen saturation in the feet must be checked. Eisenmenger's PDA is further discussed in a separate section of the present guidelines series. Heart catheterization (to determine PAPs and resistances with • testing of pulmonary vascular reactivity using prostacyclin, inhaled oxygen and nitric oxide if PAPs are greater than two-thirds the systemic pressures). Coronary angiography in patients at risk for coronary artery disease or • in patients older than 40 years of age if an intervention is planned. MRI or CT scan to define the anatomy and detect ductal aneurysm • or calcification. MRI can also be used to estimate Qp:Qs.
Part IV. Diagnostic workup
Part V. Indications for intervention/reintervention/medical therapy
No intervention is indicated if a small silent PDA is detected.
Class I, level C
The following situations warrant intervention:
• The presence of a PDA (except the silent duct at one extreme and the presence of severe, irreversible pulmonary vascular disease at the other extreme).
• Closure of a small but audible PDA is usually recommended, although this indication remains controversial given the low perceived risk of endarteritis.
• The occurrence of an episode of endarteritis on a clinically silent PDA.
• If pulmonary hypertension is present (PAP greater than two-thirds the SABP or pulmonary arteriolar resistance greater than two-thirds the systemic arteriolar resistance), there must be a net left-to-right shunt of at least 1.5:1, or evidence of pulmonary artery reactivity when challenged with a pulmonary vasodilator (eg, oxygen, nitric oxide and/or prostaglandin).
Class IIa, level B (64,65)
If PAH is present (PAP greater than two-thirds the SABP or pulmonary arterial resistance greater than two-thirds the systemic arteriolar resistance) and irreversible, the PDA should not be closed. Such patients should receive care from a specialist with expertise in CHD and PAH. Class III, level C
Part VI. Surgical/interventional technical options
Device closure is the preferred method for the small ductus and, when possible, should be planned at the same time as the diagnostic catheterization. The presence of ductal calcification increases surgical risk and favours device closure. Class I, level B (66,67) Part VII. Surgical/interventional outcomes Surgical closure should be reserved for those in whom the PDA is too large for device closure. Examples in which the ductal anatomy may be so distorted that it is not acceptable for device closure might include aneurysm or postendarteritis. Operative repair should be undertaken by congenital heart surgeons.
Class I, level C (68,69)
Device closure: Successful closure is achieved in the large majority of attempts using a variety of devices (66, 70, 71) . More than 85% of ducts are fully occluded by one year following device placement; these results have continued to improve with newer devices. Recanalization is rare but can occur. Surgical closure: More than 95% of ducts can be closed by surgery. Recanalization is unusual but recognized. Postoperative complications may include recurrent laryngeal or phrenic nerve damage, and thoracic duct damage.
Part VIII. Arrhythmias
Atrial fibrillation may occur in older adults.
Part IX. Pregnancy and contraception
Pregnancy is well tolerated in women with silent and small PDA or in patients in functional class 1 or 2 before pregnancy. Global (ventricular systolic dysfunction, degree of cyanosis, history of cardiac complications) (35) and lesion-specific risks must be taken into account when determining the risk of pregnancy.
Pregnancy in women with Eisenmenger's syndrome is not advised because of the high maternal and fetal mortality. Class III, level B (36-39)
Part X. Follow-up
Patients who have been repaired should have periodic evaluation by an ACHD cardiologist because recanalization can occur or residual problems (pulmonary hypertension, LV dysfunction, atrial fibrillation) may persist or develop. Patients with devices in situ should be followed periodically because the natural history of these devices is unknown. Endocarditis prophylaxis is recommended for six months following PDA closure (surgical or device) or for life if any residual defect persists.
Class IIa, level B (40)
Endocarditis prophylaxis is not recommended in patients with an isolated PDA.
Class III, level B (40)
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